Study M1007
Study name | Bu QP 2022 |
Title | The antidepressant effects and serum metabonomics of bifid triple viable capsule in a rat model of chronic unpredictable mild stress |
Overall design | The aim of this study was to explore the potential mechanism of bifid triple viable capsules in the treatment of depression from the metabolite level based on the chronic unpredictable mild stress (CUMS) model. Sprague-Dawley rats were divided into the following 5 groups (n = 5 in each group): (1) control group, (2) CUMS group, (3) CUMS + fluoxetine group (stressor, with fluoxetine treatment at the dose of 2 mg/kg), (4) CUMS + bifid triple viable capsules group (stressor, with bifid triple viable capsules treatment at the dose of 20 mg/kg), and (5) CUMS + fluoxetine + bifid triple viable capsules group (stressor, with fluoxetine treatment at the dose of 2 mg/kg, and bifid triple viable capsules treatment at the dose of 20 mg/kg). The CUMS stress procedure lasted for 34 days, and drugs were administered via intragastric during the last 20 days of the model building period. Changes in serum metabolites were detected via LC-MS-based non-targeted metabolomics (n =5/group). |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Rat; Sprague-Dawley rat; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; |
Criteria for depression | Not reported |
Sample size | 25 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: ultra-performance liquid chromatography (Waters, USA) with Q-TOF high-resolution mass spectrometer (Triple TOF 6600, AB SCIEX, USA); |
PMID | |
DOI | |
Citation | Bu Q, Zhang J, Guo X, et al. The antidepressant effects and serum metabonomics of bifid triple viable capsule in a rat model of chronic unpredictable mild stress. Front Nutr. 2022 Sep 15;9:947697. |
Metabolite | Arachidonic acid; Propionylcarnitine; Glycocholic acid; Oleoylethanolamide; Eicosapentaenoic acid; LysoPC(24:0/0:0); PC(14:0/20:1(11Z)); D-Phenylalanine; PC(O-14:0/O-1:0); Sclareol; Mesterolone; Vetiveryl acetate; Myristoylcarnitine; PA(13:0/22:0); Kalihinol A; |
